Cargando…

Quantifying and predicting the effect of anti-TNF therapy on axSpA-related fatigue: results from the BSRBR-AS registry and meta-analysis

OBJECTIVES: Effective management of axial spondyloarthritis (axSpA)-related fatigue is a major unmet clinical need. Anti-TNF therapy may reduce fatigue levels, although any effect has yet to be definitively quantified and predictors of any such improvements are unknown. METHODS: The British Society...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shim, Joanna, Dean, Linda E, Karabayas, Maira, Jones, Gareth T, Macfarlane, Gary J, Basu, Neil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590410/ https://www.ncbi.nlm.nih.gov/pubmed/32337555 http://dx.doi.org/10.1093/rheumatology/keaa132

Ejemplares similares

Predicting response to anti-TNFα therapy among patients with axial spondyloarthritis (axSpA): results from BSRBR-AS
por: Macfarlane, Gary J, et al.
Publicado: (2020)

AxSpA patients who also meet criteria for fibromyalgia: identifying distinct patient clusters using data from a UK national register (BSRBR-AS)
por: Macfarlane, Gary J., et al.
Publicado: (2019)

Comorbidity and response to TNF inhibitors in axial spondyloarthritis: longitudinal analysis of the BSRBR-AS
por: Zhao, Sizheng Steven, et al.
Publicado: (2020)

Non-radiographic versus radiographic axSpA: what’s in a name?
por: Michelena, Xabier, et al.
Publicado: (2020)

Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Advances in Classification, Imaging and Therapy
por: Robinson, Philip C., et al.
Publicado: (2019)

How Has Molecular Biology Enhanced Our Undertaking of axSpA and Its Management
por: Fatica, Mauro, et al.
Publicado: (2022)

Quality and acceptability of patient-reported outcome measures used to assess fatigue in axial spondyloarthritis (axSpA): a systematic review (protocol)
por: Pearson, Nathan A., et al.
Publicado: (2018)

Depressive symptoms are associated with fatigue, poorer functional status and less engagement in sports in axSpA and PsA: an analysis from the RABBIT-SpA cohort
por: Reich, Andreas, et al.
Publicado: (2023)

Impact of biological therapy on work outcomes in patients with axial spondyloarthritis: results from the British Society for Rheumatology Biologics Register (BSRBR-AS) and meta-analysis
por: Shim, Joanna, et al.
Publicado: (2018)

Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: an analysis of the German register RABBIT-SpA
por: Regierer, Anne Constanze, et al.
Publicado: (2023)

Sera of patients with axial spondyloarthritis (axSpA) enhance osteoclastogenic potential of monocytes isolated from healthy individuals
por: Korkosz, Mariusz, et al.
Publicado: (2018)

Sustained low functional impairment in axial spondyloarthritis (axSpA): which are the primary outcomes that should be targeted to achieve this?
por: Maksymowych, Walter P., et al.
Publicado: (2023)

Association of anxiety, depression and resilience with overall health and functioning in axial spondyloarthritis (axSpA): a cross-sectional study
por: Chung, Deborah Xin Yi, et al.
Publicado: (2023)

Association between comorbidities and disease activity in axial spondyloarthritis: results from the BSRBR-AS
por: Zhao, Sizheng Steven, et al.
Publicado: (2020)

Structural Lesion Progression of the Sacroiliac Joint and Clinical Features in axSpA During TNFi Reduction: A Retrospective Cohort Study
por: Mo, Qian, et al.
Publicado: (2021)

Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA
por: van der Heijde, Désirée, et al.
Publicado: (2017)

Facet joint ankylosis in r-axSpA: detection and 2-year progression on whole spine low-dose CT and comparison with syndesmophyte progression
por: Stal, Rosalinde, et al.
Publicado: (2020)

Beantwortung epidemiologisch-rheumatologischer Fragestellungen durch Kooperation mit der bevölkerungsbasierten SHIP-Kohorte – Erkenntnisse für die Diagnostik der axialen Spondyloarthritis (axSpA)
por: Braun, J., et al.
Publicado: (2021)

Impact of TNF inhibitor therapy on joint replacement rates in rheumatoid arthritis: a matched cohort analysis of BSRBR-RA UK registry data
por: Hawley, Samuel, et al.
Publicado: (2019)

Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial
por: van der Heijde, Désirée, et al.
Publicado: (2018)

Characteristics of patients initiating treatment with baricitinib and outcomes at follow-up: analysis of BSRBR-RA Registry data
por: Edwards, Christopher J, et al.
Publicado: (2023)

Early response to anti-TNF predicts long-term outcomes including sustained remission: an analysis of the BSRBR-RA
por: Hamann, Philip D H, et al.
Publicado: (2020)

Multi-b-values-fitting readout-segmentation of long variable echo-trains diffusion-weighted imaging (RESOLVE DWI) in evaluation of disease activity and curative effect of axial spondyloarthritis (axSpA)
por: Chen, Xianyuan, et al.
Publicado: (2023)

The British Society for Rheumatology Biologics Registers in Ankylosing Spondylitis (BSRBR-AS) study: Protocol for a prospective cohort study of the long-term safety and quality of life outcomes of biologic treatment
por: Macfarlane, Gary J., et al.
Publicado: (2015)

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)
por: Dixon, W G, et al.
Publicado: (2009)

Comment on: Evaluation of adjunctive mycophenolate for large vessel giant cell arteritis. Reply
por: Karabayas, Maira
Publicado: (2021)

Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2023)

Using Microsoft Dynamics AX: the new dynamics 'AX 7'
por: Luszczak, Andreas
Publicado: (2016)

Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA
por: Jani, Meghna, et al.
Publicado: (2017)

Correction: Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA
Publicado: (2017)

The spindle gets the Axs
por: LeBrasseur, Nicole
Publicado: (2003)

Non-anti TNF biologic modifier drugs in non-infectious refractory chronic uveitis: the current evidence from a systematic review
por: Simonini, Gabriele, et al.
Publicado: (2014)

Evaluation of adjunctive mycophenolate for large vessel giant cell arteritis
por: Karabayas, Maira, et al.
Publicado: (2020)

AxPcoords & parallel AxParafit: statistical co-phylogenetic analyses on thousands of taxa
por: Stamatakis, Alexandros, et al.
Publicado: (2007)

Defining and quantifying fatigue in the rugby codes
por: Naughton, Mitchell, et al.
Publicado: (2023)

The prevalence of fibromyalgia in axial spondyloarthritis
por: Jones, Gareth T., et al.
Publicado: (2020)

A real-world assessment of mycophenolate mofetil for remission induction in eosinophilic granulomatosis with polyangiitis
por: Philobos, Mariana, et al.
Publicado: (2021)

Performance of the AX-PET demonstrator
por: Beltrame, P, et al.
Publicado: (2011)

XML Publishing with AxKit
por: Hampton, Kip
Publicado: (2004)

Risk Factors for Severe Outcomes in Patients With Systemic Vasculitis and COVID‐19: A Binational, Registry‐Based Cohort Study
por: Rutherford, Matthew A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2lfvqbrui6ecunmkfqgshc5s0k